DSpace@İnönü

Yazar "Hacibekiroglu, T" için Araştırma Çıktıları | Pubmed İndeksli Yayınlar Koleksiyonu listeleme

Yazar "Hacibekiroglu, T" için Araştırma Çıktıları | Pubmed İndeksli Yayınlar Koleksiyonu listeleme

Sırala: Sıra: Sonuçlar:

  • Convalescent plasma therapy in patients withCOVID-19 
    Yigenoglu, TN; Hacibekiroglu, T; Berber, I; Dal Sinan, M; Basturk, A; Namdaroglu, S; Korkmaz, S; Ulas, T; Dal, T; Erkurt, MA; Turgut, B; Altuntas, F (2020)
    There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ...
  • Convalescent plasma therapy in patients withCOVID-19 
    Yigenoglu, TN; Hacibekiroglu, T; Berber, I; Dal Sinan, M; Basturk, A; Namdaroglu, S; Korkmaz, S; Ulas, T; Dal, T; Erkurt, MA; Turgut, B; Altuntas, F (2020)
    There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ...
  • Convalescent plasma therapy in patients withCOVID-19 
    Yigenoglu, TN; Hacibekiroglu, T; Berber, I; Dal Sinan, M; Basturk, A; Namdaroglu, S; Korkmaz, S; Ulas, T; Dal, T; Erkurt, MA; Turgut, B; Altuntas, F (2020)
    There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ...
  • Outcome of COVID-19 in patients with chronic myeloid leukemia receiving 
    Basci, S; Ata, N; Altuntas, F; Yigenoglu, TN; Dal, MS; Korkmaz, S; Namdaroglu, S; Basturk, A; Hacibekiroglu, T; Dogu, MH; Berber, I; Dal, K; Erkurt, MA; Turgut, B; Caglayan, M; Ayvali, MO; Celik, O; Ulgu, MM; Birinci, S (2020)
    Introduction In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). Method The data of 16 laboratory-confirmed COVID-19 patients with ...
  • Convalescent plasma therapy in patients withCOVID-19 
    Yigenoglu, TN; Hacibekiroglu, T; Berber, I; Dal Sinan, M; Basturk, A; Namdaroglu, S; Korkmaz, S; Ulas, T; Dal, T; Erkurt, MA; Turgut, B; Altuntas, F (2020)
    There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ...
  • Convalescent plasma therapy in patients withCOVID-19 
    Yigenoglu, TN; Hacibekiroglu, T; Berber, I; Dal Sinan, M; Basturk, A; Namdaroglu, S; Korkmaz, S; Ulas, T; Dal, T; Erkurt, MA; Turgut, B; Altuntas, F (2020)
    There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ...
  • Mesenchymal stem cell transfusion: Possible beneficial effects in 
    Yigenoglu, TN; Basci, S; Sahin, D; Ulas, T; Dal, MS; Korkmaz, S; Hacibekiroglu, T; Namdaroglu, S; Erkurt, MA; Turgut, B; Altuntas, F (2021)
    SARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and ...
  • Convalescent plasma therapy in patients with COVID-19 
    Altuntas, F; Ata, N; Yigenoglu, TN; Basci, S; Dal, MS; Korkmaz, S; Namdaroglu, S; Basturk, A; Hacibekiroglu, T; Dogu, MH; Berber, I; Dal, K; Kinik, K; Haznedaroglu, I; Yilmaz, FM; Kilic, I; Demircioglu, S; Yosunkaya, A; Erkurt, MA; Turgut, B; Caglayan, M; Celik, O (2021)
    Introduction: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and ...
  • Convalescent plasma therapy in patients with COVID-19 
    Altuntas, F; Ata, N; Yigenoglu, TN; Basci, S; Dal, MS; Korkmaz, S; Namdaroglu, S; Basturk, A; Hacibekiroglu, T; Dogu, MH; Berber, I; Dal, K; Kinik, K; Haznedaroglu, I; Yilmaz, FM; Kilic, I; Demircioglu, S; Yosunkaya, A; Erkurt, MA; Turgut, B; Caglayan, M; Celik, O (2021)
    Introduction: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and ...
  • COVID-19 in hematopoietic cell transplant recipients 
    Altuntas, F; Ata, N; Yigenoglu, TN; Basci, S; Dal, MS; Korkmaz, S; Namdaroglu, S; Basturk, A; Hacibekiroglu, T; Dogu, MH; Berber, I; Dal, K; Erkurt, MA; Turgut, B; Ulgu, MM; Celik, O; Akunal, A; Birinci, S (2021)
    In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A ...
  • The outcome of COVID-19 in patients with hematological malignancy 
    Yigenoglu, TN; Ata, N; Altuntas, F; Basci, S; Dal, MS; Korkmaz, S; Namdaroglu, S; Basturk, A; Hacibekiroglu, T; Dogu, MH; Dal, K; Erkurt, MA; Turgut, B; Ulgu, MM; Celik, O; Imrat, E; Birinci, S (2021)
    In this study, we aim to report the outcomes for COVID-19 in patients with hematological malignancy in Turkey. Data from laboratory-confirmed 188 897 COVID-19 patients diagnosed between 11 March 2020 and 22 June 2020 ...
  • COVID-19 in hematopoietic cell transplant recipients 
    Altuntas, F; Ata, N; Yigenoglu, TN; Basci, S; Dal, MS; Korkmaz, S; Namdaroglu, S; Basturk, A; Hacibekiroglu, T; Dogu, MH; Berber, I; Dal, K; Erkurt, MA; Turgut, B; Ulgu, MM; Celik, O; Akunal, A; Birinci, S (2021)
    In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A ...
  • Convalescent plasma therapy in patients with COVID-19 
    Altuntas, F; Ata, N; Yigenoglu, TN; Basci, S; Dal, MS; Korkmaz, S; Namdaroglu, S; Basturk, A; Hacibekiroglu, T; Dogu, MH; Berber, I; Dal, K; Kinik, K; Haznedaroglu, I; Yilmaz, FM; Kilic, I; Demircioglu, S; Yosunkaya, A; Erkurt, MA; Turgut, B; Caglayan, M; Celik, O (2021)
    Introduction: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and ...
  • Convalescent plasma therapy in patients with COVID-19 
    Altuntas, F; Ata, N; Yigenoglu, TN; Basci, S; Dal, MS; Korkmaz, S; Namdaroglu, S; Basturk, A; Hacibekiroglu, T; Dogu, MH; Berber, I; Dal, K; Kinik, K; Haznedaroglu, I; Yilmaz, FM; Kilic, I; Demircioglu, S; Yosunkaya, A; Erkurt, MA; Turgut, B; Caglayan, M; Celik, O (2021)
    Introduction: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and ...
  • Convalescent plasma therapy in patients with COVID-19 
    Altuntas, F; Ata, N; Yigenoglu, TN; Basci, S; Dal, MS; Korkmaz, S; Namdaroglu, S; Basturk, A; Hacibekiroglu, T; Dogu, MH; Berber, I; Dal, K; Kinik, K; Haznedaroglu, I; Yilmaz, FM; Kilic, I; Demircioglu, S; Yosunkaya, A; Erkurt, MA; Turgut, B; Caglayan, M; Celik, O (2021)
    Introduction: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and ...